Radiation protection effect of curcumin in patients with thyroid cancer treated with 131-I
- Conditions
- differentiated thyroid carcinoma(DTC).Malignant neoplasm of thyroid gland
- Registration Number
- IRCT2016020526377N1
- Lead Sponsor
- Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
All patients with differentiated thyroid cancer (follicular, papillary or mixed type) don't received destroying dose (ablative dose) of radioiodine up to now; no palpable neck mass; thyroid pathology reported there is no invasion to capsular and lymph areas and blood vessels; body scan with 131-I don’t show any functional tissue in regions other than the thyroid bed; thyroid cancer confirmed by biopsy; all patients have total thyroidectomy; TSH level before administration of radioiodine is higher than 30 IU/ML.
exclusion criteria: after treatment with 131 I if there is abnormal tissue absorption of iodine in other areas of the thyroid bed; if patients after taking the first capsule of curcumin had a headache and dizziness; patient will be excluded.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MN counts in 1000 BN cells. Timepoint: before and 7 days after radioiodine therapy. Method of measurement: blood sampling.
- Secondary Outcome Measures
Name Time Method ymphocyte and platelets count. Timepoint: before and 1 week after radioiodine therapy. Method of measurement: blood sample/ CBC.